Drug Profile
Research programme: monoclonal antibody-based therapeutics - Compugen
Alternative Names: Antibody-based cancer immunotherapies - Compugen; Cancer immunotherapies - Compugen; CGEN 15027-targeted mAb; CGEN 15027-targeted monoclonal antibody; CGEN 15032-targeted immunotherapeutic; CGEN 15052-targeted mAb; CGEN 15052-targeted monoclonal antibody; CGEN 15137-targeted antibody; CGEN 15137/TIGIT; CGEN 671-targeted mAb; CGEN 671-targeted monoclonal antibody; CGEN XXXX; CGEN-15022-targeted mAb; CGEN-15022-targeted monoclonal antibody; CGEN-15049-targeted mAb; CGEN-15049-targeted monclonal antibody; CGEN-928-targeted mAb; CGEN-928-targeted monoclonal antibody; Immune checkpoint-targeted monoclonal antibodies - Compugen; Splice variant-targeted monoclonal antibody therapeutics - CompugenLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Compugen
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B7 antigen inhibitors; CD28 antigen inhibitors; Immunomodulators; Membrane protein inhibitors; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Haematological malignancies; Malignant melanoma; Multiple myeloma; Solid tumours
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
- 06 Aug 2019 Preclinical trials in Cancer in Israel (Parenteral) before August 2019 (Compugen pipeline, August 2019)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Parenteral)